Thymosin alpha-1
Recovery · Immunomodulatory peptide
Tier B+
What this is
Approved in >30 countries (not US). Wu 2013 meta-analysis in sepsis showed mortality benefit. Used in long-COVID, Lyme, and chronic fatigue protocols with weak evidence. Same Jan 2025 FDA compounding restriction. Generally considered one of the better-studied 'biohacker peptides.'
Mechanism
28-amino-acid peptide derived from thymus prothymosin alpha; stimulates TLR9/Th1 immunity; activates dendritic cells and T-cell maturation; used in Europe/Asia for hepatitis B/C, sepsis, as vaccine adjuvant
Dose & route
1.6 mg subQ 2x/week (hepatitis indications); biohacker dosing similar
Citations
- https://pubmed.ncbi.nlm.nih.gov/23442320/
- https://pubmed.ncbi.nlm.nih.gov/30700018/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7232131/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.